The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England

Abstract

Olanzapine is an ‘atypical’ antipsychotic indicated for the treatment of schizophrenia. We analysed adverse events (AEs) reported in primary practice in England. Dispensed prescriptions issued between December 1996 and May 1998 provided exposure data. Questionnaires sent to general practitioners provided outcomes. Frequently reported AEs were: drowsiness/sedation (n = 19), extrapyramidal disorder (n = 13) and unspecified side-effects (n = 33). Events with highest incidence density in first month and reason for stopping were: drowsiness/sedation [n = 153, incidence density (ID)1 18.9], weight gain (n = 117, ID1 8.9) and malaise/lassitude (n = 65, ID1 5.2). Extrapyramidal disorders were more common in elderly population (> 70 years, ID1 3.6, risk 26.0 per 1000 patients) compared to < 70 years (ID1 1.1, risk 8.4 per 1000 patients). Serious suspected adverse reactions were neuroleptic malignant syndrome (n = 1) and angioneurotic ooedema (n = 2). There were eight reports of diabetes mellitus assessed as possibly due to olanzapine. Diabetes mellitus was an unlabelled AE and possible signal generated by prescription-event monitoring.

Keywords

adverse drug reaction (ADR)atypical antipsychotic extrapyramidal disorder incidence density (ID)prescription-event monitoring (PEM)

Get full access to this article

View all access options for this article.

References

Anon (1996) New drugs in clinical development: olanzapine. UK Drug Information Services (produced by a consortium of Regional Drug Information Centres)

Association of the British Pharmaceutical Industry (1998) Compendium. Datapharm Publications Ltd, London

Barnes T R (1989) A rating scale for drug induced akathasia. Br J Psychiatry 54: 672–676

Beasley Jr C M , Tollefson G D , Tran P V (1997) Safety of olanzapine. J Clin Psychiatry 58(Suppl. 10): 13–17

CIOMS/WHO (1993) International ethical guidelines for biomedical research involving human subjects. CIOMS/WHO, Geneva

Freemantle S N , Pearce G L , Wilton L V , Mann R D (1997) The incidence of the most commonly reported events with 40 newly marketed drugs – a study by Prescription-Event Monitoring. Pharmacoepidemiol Drug Safety 6(Suppl. 1): 1–8

Gilbert P L , Harris M J , McAdams L A et al. (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 52: 173–188

Goldberg D , Tantam, D (1991) The public health impact of mental disorders. In Holland W W , Detels R , Knox G (eds), Oxford textbook of public health. Application in public health, 2nd edn, vol. 3, pp. 268–269. Oxford University Press, Oxford

Hale T (1993) Will the new antipsychotics improve the treatment of schizophrenia? Depot preparations still hold the key to compliance. BMJ 307: 749–780

10.

Mackay F J , Wilton L V , Pearce G L , Freemantle S N , Mann R D (1998) The safety of risperidone: a postmarketing study on 7684 patients. Hum Psychopharmacol Clin Exp 13: 413–418

11.

McAvoy B R , Kramer E F S (1996) General practice postal surveys: a questionnaire too far? BMJ 313: 732–733

12.

Reus V (1997) Olanzapine: a novel atypical neuroleptic agent. Lancet 349: 1264–1265

13.

Royal College of Physicians of London (1996) Guidelines on the practice of ethical committees in medical research involving human subjects. Royal College of Physicians, London

14.

Shergill S , Murray R (1997) Olanzapine: a new atypical drug for schizophrenia. Prescriber 8: 59–62

15.

Templeton L , Deeham A , Taylor C , Drummond C , Strang J (1997) Surveying general practitioners: does a low response rate matter? Br J Gen Pract 47: 91–94